Evidence map›Paper›PMID 37584407›Full record

ArticleMolecular oncology2023

Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study.

Shengyu Zhou, Fayan Zhang, Mengxiang Xu, Lei Zhang, Zhengchuang Liu, Qiong Yang, Chunyang Wang, Baoming Wang, Tonghui Ma, Jiao Feng

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontiers in oncology · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Shengyu ZhouClinical Nursing Department, School of Nursing and Rehabilitation, Cheeloo College of Medicine, Shandong University, Jinan, China.
Fayan ZhangCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Mengxiang XuJichenjunchuang Clinical Laboratory, Hangzhou, China.
Lei ZhangCancer Center, Daping Hospital, Army Medical University, Chongqing, China.
Zhengchuang LiuKey Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, China.
Qiong YangGeneral Surgery, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), China.
Chunyang WangJichenjunchuang Clinical Laboratory, Hangzhou, China.
Baoming WangJichenjunchuang Clinical Laboratory, Hangzhou, China.
Tonghui MaJichenjunchuang Clinical Laboratory, Hangzhou, China.ORCID 0000-0002-5414-0522
Jiao FengCancer Center, Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, China.ORCID 0000-0001-6128-851X
Hangzhou DAC Biotech (China) · CNZhejiang Provincial People's Hospital · CNArmy Medical University · CNHangzhou Normal University · CNShandong University · CNShandong University of Traditional Chinese Medicine · CN

Funding

Zhejiang Province Medical and Health Research Projects 2016KYB027Zhejiang Province Medical and Health Research Projects 2017KY010
6 · The paper itself

Abstract

ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) rearrangements are a crucial therapeutic target in non-small cell lung cancer (NSCLC). However, there is limited comprehensive analysis of the molecular patterns of ROS1 fusions. This study aimed to address this gap by analysing 135 ROS1 fusions from 134 Chinese NSCLC patients using next-generation sequencing (NGS). The fusions were categorized into common and uncommon based on their incidence. Our study revealed, for the first time, a unique distribution preference of breakpoints within ROS1, with common fusions occurring in introns 31-33 and uncommon fusions occurring in introns 34 and 35. Additionally, we identified previously unknown breakpoints within intron 28 of ROS1. Furthermore, we identified a close association between the distribution patterns of fusion partners and breakpoints on ROS1, providing important insights into the molecular landscape of ROS1 fusions. We also confirmed the presence of inconsistent breakpoints in ROS1 fusions between DNA-based NGS and RNA-based NGS through rigorous validation methods. These inconsistencies were attributed to alternative splicing resulting in out-of-frame or exonic ROS1 fusions. These findings significantly contribute to our understanding of the molecular characteristics of ROS1 fusions, which have implications for panel design and the treatment of NSCLC patients with ROS1 rearrangements.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsOncogene Proteins, FusionProtein-Tyrosine KinasesProto-Oncogene ProteinsAdultAgedChinaCohort StudiesEast Asian PeopleFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedProto-Oncogene MasMAS1 protein, humanOncogene Proteins, FusionProtein-Tyrosine KinasesProto-Oncogene MasProto-Oncogene ProteinsROS1 protein, humanChineseDNA-NGSNSCLCRNA-NGSROS1

Identifiers

PMID37584407
PMCPMC10552890
OpenAlexW4385850889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.